Cargando…

Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes

RATIONALE & OBJECTIVE: Biomarkers of kidney disease progression have been identified in individuals with diabetes and underlying chronic kidney disease (CKD). Whether or not these markers are associated with the development of CKD in a general population without diabetes or CKD is not well estab...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Dustin, Chen, Jingsha, Shlipak, Michael G., Ix, Joachim H., Sarnak, Mark J., Gutierrez, Orlando M., Schelling, Jeffrey R., Bonventre, Joseph V., Sabbisetti, Venkata S., Schrauben, Sarah J., Coca, Steven G., Kimmel, Paul L., Vasan, Ramachandran S., Grams, Morgan E., Parikh, Chirag, Coresh, Josef, Rebholz, Casey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568645/
https://www.ncbi.nlm.nih.gov/pubmed/37841418
http://dx.doi.org/10.1016/j.xkme.2023.100719
_version_ 1785119395408773120
author Le, Dustin
Chen, Jingsha
Shlipak, Michael G.
Ix, Joachim H.
Sarnak, Mark J.
Gutierrez, Orlando M.
Schelling, Jeffrey R.
Bonventre, Joseph V.
Sabbisetti, Venkata S.
Schrauben, Sarah J.
Coca, Steven G.
Kimmel, Paul L.
Vasan, Ramachandran S.
Grams, Morgan E.
Parikh, Chirag
Coresh, Josef
Rebholz, Casey M.
author_facet Le, Dustin
Chen, Jingsha
Shlipak, Michael G.
Ix, Joachim H.
Sarnak, Mark J.
Gutierrez, Orlando M.
Schelling, Jeffrey R.
Bonventre, Joseph V.
Sabbisetti, Venkata S.
Schrauben, Sarah J.
Coca, Steven G.
Kimmel, Paul L.
Vasan, Ramachandran S.
Grams, Morgan E.
Parikh, Chirag
Coresh, Josef
Rebholz, Casey M.
author_sort Le, Dustin
collection PubMed
description RATIONALE & OBJECTIVE: Biomarkers of kidney disease progression have been identified in individuals with diabetes and underlying chronic kidney disease (CKD). Whether or not these markers are associated with the development of CKD in a general population without diabetes or CKD is not well established. STUDY DESIGN: Prospective observational cohort. SETTING & PARTICIPANTS: In the Atherosclerosis Risk in Communities) study, 948 participants were studied. EXPOSURES: The baseline plasma biomarkers of kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), soluble urokinase plasminogen activator receptor (suPAR), tumor necrosis factor receptor 1 (TNFR-1), tumor necrosis factor receptor 2 (TNFR-2), and human cartilage glycoprotein-39 (YKL-40) measured in 1996-1998. OUTCOME: Incident CKD after 15 years of follow-up defined as ≥40% estimated glomerular filtration rate decline to <60 mL/min/1.73 m(2) or dialysis dependence through United States Renal Data System linkage. ANALYTICAL APPROACH: Logistic regression and C statistics. RESULTS: There were 523 cases of incident CKD. Compared with a random sample of 425 controls, there were greater odds of incident CKD per 2-fold higher concentration of KIM-1 (OR, 1.49; 95% CI, 1.25-1.78), suPAR (OR, 2.57; 95% CI, 1.74-3.84), TNFR-1 (OR, 2.20; 95% CI, 1.58-3.09), TNFR-2 (OR, 2.03; 95% CI, 1.37-3.04). After adjustment for all biomarkers, KIM-1 (OR, 1.42; 95% CI, 1.19-1.71), and suPAR (OR, 1.86; 95% CI, 1.18-2.92) remained associated with incident CKD. Compared with traditional risk factors, the addition of all 6 biomarkers improved the C statistic from 0.695-0.731 (P < 0.01) and using the observed risk of 12% for incident CKD, the predicted risk gradient changed from 5%-40% (for the 1st–5th quintile) to 4%-44%. LIMITATIONS: Biomarkers and creatinine were measured at one time point. CONCLUSIONS: Higher levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with higher odds of incident CKD among individuals without diabetes. PLAIN-LANGUAGE SUMMARY: For people with diabetes or kidney disease, several biomarkers have been shown to be associated with worsening kidney disease. Whether these biomarkers have prognostic significance in people without diabetes or kidney disease is less studied. Using the Atherosclerosis Risk in Communities study, we followed individuals without diabetes or kidney disease for an average of 15 years after biomarker measurement to see if these biomarkers were associated with the development of kidney disease. We found that elevated levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with the development of kidney disease. These biomarkers may help identify individuals who would benefit from interventions to prevent the development of kidney disease.
format Online
Article
Text
id pubmed-10568645
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105686452023-10-13 Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes Le, Dustin Chen, Jingsha Shlipak, Michael G. Ix, Joachim H. Sarnak, Mark J. Gutierrez, Orlando M. Schelling, Jeffrey R. Bonventre, Joseph V. Sabbisetti, Venkata S. Schrauben, Sarah J. Coca, Steven G. Kimmel, Paul L. Vasan, Ramachandran S. Grams, Morgan E. Parikh, Chirag Coresh, Josef Rebholz, Casey M. Kidney Med Original Research RATIONALE & OBJECTIVE: Biomarkers of kidney disease progression have been identified in individuals with diabetes and underlying chronic kidney disease (CKD). Whether or not these markers are associated with the development of CKD in a general population without diabetes or CKD is not well established. STUDY DESIGN: Prospective observational cohort. SETTING & PARTICIPANTS: In the Atherosclerosis Risk in Communities) study, 948 participants were studied. EXPOSURES: The baseline plasma biomarkers of kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), soluble urokinase plasminogen activator receptor (suPAR), tumor necrosis factor receptor 1 (TNFR-1), tumor necrosis factor receptor 2 (TNFR-2), and human cartilage glycoprotein-39 (YKL-40) measured in 1996-1998. OUTCOME: Incident CKD after 15 years of follow-up defined as ≥40% estimated glomerular filtration rate decline to <60 mL/min/1.73 m(2) or dialysis dependence through United States Renal Data System linkage. ANALYTICAL APPROACH: Logistic regression and C statistics. RESULTS: There were 523 cases of incident CKD. Compared with a random sample of 425 controls, there were greater odds of incident CKD per 2-fold higher concentration of KIM-1 (OR, 1.49; 95% CI, 1.25-1.78), suPAR (OR, 2.57; 95% CI, 1.74-3.84), TNFR-1 (OR, 2.20; 95% CI, 1.58-3.09), TNFR-2 (OR, 2.03; 95% CI, 1.37-3.04). After adjustment for all biomarkers, KIM-1 (OR, 1.42; 95% CI, 1.19-1.71), and suPAR (OR, 1.86; 95% CI, 1.18-2.92) remained associated with incident CKD. Compared with traditional risk factors, the addition of all 6 biomarkers improved the C statistic from 0.695-0.731 (P < 0.01) and using the observed risk of 12% for incident CKD, the predicted risk gradient changed from 5%-40% (for the 1st–5th quintile) to 4%-44%. LIMITATIONS: Biomarkers and creatinine were measured at one time point. CONCLUSIONS: Higher levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with higher odds of incident CKD among individuals without diabetes. PLAIN-LANGUAGE SUMMARY: For people with diabetes or kidney disease, several biomarkers have been shown to be associated with worsening kidney disease. Whether these biomarkers have prognostic significance in people without diabetes or kidney disease is less studied. Using the Atherosclerosis Risk in Communities study, we followed individuals without diabetes or kidney disease for an average of 15 years after biomarker measurement to see if these biomarkers were associated with the development of kidney disease. We found that elevated levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with the development of kidney disease. These biomarkers may help identify individuals who would benefit from interventions to prevent the development of kidney disease. Elsevier 2023-08-25 /pmc/articles/PMC10568645/ /pubmed/37841418 http://dx.doi.org/10.1016/j.xkme.2023.100719 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Le, Dustin
Chen, Jingsha
Shlipak, Michael G.
Ix, Joachim H.
Sarnak, Mark J.
Gutierrez, Orlando M.
Schelling, Jeffrey R.
Bonventre, Joseph V.
Sabbisetti, Venkata S.
Schrauben, Sarah J.
Coca, Steven G.
Kimmel, Paul L.
Vasan, Ramachandran S.
Grams, Morgan E.
Parikh, Chirag
Coresh, Josef
Rebholz, Casey M.
Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes
title Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes
title_full Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes
title_fullStr Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes
title_full_unstemmed Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes
title_short Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes
title_sort plasma biomarkers and incident ckd among individuals without diabetes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568645/
https://www.ncbi.nlm.nih.gov/pubmed/37841418
http://dx.doi.org/10.1016/j.xkme.2023.100719
work_keys_str_mv AT ledustin plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT chenjingsha plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT shlipakmichaelg plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT ixjoachimh plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT sarnakmarkj plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT gutierrezorlandom plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT schellingjeffreyr plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT bonventrejosephv plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT sabbisettivenkatas plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT schraubensarahj plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT cocasteveng plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT kimmelpaull plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT vasanramachandrans plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT gramsmorgane plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT parikhchirag plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT coreshjosef plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT rebholzcaseym plasmabiomarkersandincidentckdamongindividualswithoutdiabetes
AT plasmabiomarkersandincidentckdamongindividualswithoutdiabetes